Consensus Amgen Inc. Buenos Aires S.E.

Stocks

AMGN

ARDEUT110665

Pharmaceuticals

End-of-day quote Buenos Aires S.E. 27/10/2026			5-day change	1st Jan Change
24,640.00 ^ARS	-0.69%		+3.75%	+47.81%

10-27	Amgen Announces Dividend for the Fourth Quarter of 2026, Payable on December 11, 2026	CI
10-27	Amgen Announces New Data Presentations Across Rare And Other Serious Autoimmune Diseases At ACR Convergence 2026	CI

3bd7c8f4003d22c6504d.E141bzgd2yBVCgmtpCmsJ6XqAaOkly46AF9ISf9Lc10.WDV-J01fiEMvRTn4wVjrfsOTYMTB_xtMSQUPO5gDMidYbg0iWnm-RmdkYg~96d0f01225c46e9fa45fb1c3451abf66

Analysts' recommendations: Amgen Inc.

10-26	A Week of Reckoning for Wall Street
10-26	Jefferies Adjusts Price Target on Amgen to $428 From $410	MT
10-23	Amgen's Growth Drivers, Pipeline Could Support Longer-Term Outlook, Oppenheimer Says	MT
10-23	Oppenheimer Adjusts Amgen Price Target to $480 From $450, Maintains Outperform Rating	MT
10-21	Barclays Adjusts Price Target on Amgen to $400 From $380	MT
10-15	Goldman Sachs Adjusts Price Target on Amgen to $481 From $475	MT
10-13	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT
10-12	Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says	MT
10-12	BofA Securities Adjusts Amgen Price Target to $328 From $317, Maintains Underperform Rating	MT
10-12	Wells Fargo Adjusts Price Target on Amgen to $430 From $435	MT
10-12	BMO Capital Adjusts Price Target on Amgen to $415 From $450	MT
10-09	UBS Adjusts Price Target on Amgen to $470 From $430, Maintains Buy Rating	MT
10-08	RBC Raises Price Target on Amgen to $430 From $400, Keeps Outperform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Amgen to $359 From $362	MT
09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
09-23	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
AMGEN INC.	-	-	-	-
ELI LILLY AND COMPANY				+4.04%
JOHNSON & JOHNSON				+3.97%
ABBVIE INC.				-1.12%
ROCHE HOLDING AG				-3%
MERCK & CO., INC.				+12.65%
NOVARTIS AG				-3.77%
ASTRAZENECA PLC				+23.18%
AMGEN INC.				-11.3%
GILEAD SCIENCES, INC.				+0.7%
Average				+2.82%
Weighted average by Cap.				+3.06%